Q-omics provides the consensus-scored CNTNAP3P2 profile across patient tissues and cancer cell-line models. CNTNAP3P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNTNAP3P2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CNTNAP3P2 RNA expression shows 18,013 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where CNTNAP3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNTNAP3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNTNAP3P2 survival associations across molecular data types. CNTNAP3P2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNTNAP3P2 RNA expression–survival associations across cancer types. High CNTNAP3P2 expression shows unfavorable associations in ACC, BLCA, THCA and LGG, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNTNAP3P2 RNA expression.
This table summarizes CNTNAP3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CNTNAP3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNTNAP3P2 shows lower tumor expression in KICH, LUAD, BRCA, THCA and READ and higher tumor expression in LIHC. The KICH box plot shows higher CNTNAP3P2 RNA expression in normal versus tumor tissue (log2 FC = −0.821, t-test p < 0.001).
This table shows molecular features associated with CNTNAP3P2 in patient tissues and cancer cell lines. In patient samples, CNTNAP3P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
